Stoke Therapeutics, Inc. 0GT.F Stock
Stoke Therapeutics, Inc. Price Chart
Stoke Therapeutics, Inc. 0GT.F Financial and Trading Overview
Stoke Therapeutics, Inc. stock price | 12.4 EUR |
Previous Close | 11.4 EUR |
Open | 11.7 EUR |
Bid | 11.7 EUR x N/A |
Ask | 12.1 EUR x N/A |
Day's Range | 11.7 - 11.7 EUR |
52 Week Range | 6.6 - 21.8 EUR |
Volume | 210 EUR |
Avg. Volume | 5 EUR |
Market Cap | 526.71M EUR |
Beta (5Y Monthly) | 0.39733 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.22 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 62.88 EUR |
0GT.F Valuation Measures
Enterprise Value | 254.57M EUR |
Trailing P/E | N/A |
Forward P/E | -4.77551 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 36.182472 |
Price/Book (mrq) | 2.4173553 |
Enterprise Value/Revenue | 17.488 |
Enterprise Value/EBITDA | -2.487 |
Trading Information
Stoke Therapeutics, Inc. Stock Price History
Beta (5Y Monthly) | 0.39733 |
52-Week Change | 16.92% |
S&P500 52-Week Change | 20.43% |
52 Week High | 21.8 EUR |
52 Week Low | 6.6 EUR |
50-Day Moving Average | 9.13 EUR |
200-Day Moving Average | 9.96 EUR |
0GT.F Share Statistics
Avg. Volume (3 month) | 5 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 44.19M |
Float | 18.83M |
Short Ratio | N/A |
% Held by Insiders | 5.58% |
% Held by Institutions | 92.05% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -716.15% |
Gross Margin | 100.00% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -21.80% |
Return on Equity (ttm) | -43.61% |
Income Statement
Revenue (ttm) | 14.56M EUR |
Revenue Per Share (ttm) | 0.36 EUR |
Quarterly Revenue Growth (yoy) | 71.70% |
Gross Profit (ttm) | 12.41M EUR |
EBITDA | -102355000 EUR |
Net Income Avi to Common (ttm) | -98963000 EUR |
Diluted EPS (ttm) | -2.45 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 253.67M EUR |
Total Cash Per Share (mrq) | 5.74 EUR |
Total Debt (mrq) | 4.5M EUR |
Total Debt/Equity (mrq) | 2.1 EUR |
Current Ratio (mrq) | 8.572 |
Book Value Per Share (mrq) | 4.84 |
Cash Flow Statement
Operating Cash Flow (ttm) | -85713000 EUR |
Levered Free Cash Flow (ttm) | -38745876 EUR |
Profile of Stoke Therapeutics, Inc.
Country | Germany |
State | MA |
City | Bedford |
Address | 45 Wiggins Avenue |
ZIP | 01730 |
Phone | 781 430 8200 |
Website | https://www.stoketherapeutics.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 117 |
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company is also developing STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is based in Bedford, Massachusetts.
Q&A For Stoke Therapeutics, Inc. Stock
What is a current 0GT.F stock price?
Stoke Therapeutics, Inc. 0GT.F stock price today per share is 12.4 EUR.
How to purchase Stoke Therapeutics, Inc. stock?
You can buy 0GT.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Stoke Therapeutics, Inc.?
The stock symbol or ticker of Stoke Therapeutics, Inc. is 0GT.F.
Which industry does the Stoke Therapeutics, Inc. company belong to?
The Stoke Therapeutics, Inc. industry is Biotechnology.
How many shares does Stoke Therapeutics, Inc. have in circulation?
The max supply of Stoke Therapeutics, Inc. shares is 51.86M.
What is Stoke Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Stoke Therapeutics, Inc. PE Ratio is now.
What was Stoke Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Stoke Therapeutics, Inc. EPS is -2.22 EUR over the trailing 12 months.
Which sector does the Stoke Therapeutics, Inc. company belong to?
The Stoke Therapeutics, Inc. sector is Healthcare.